The effect of carnitine supplementation in valproate‐induced hyperammonaemia
Authors:
- 1 April 1996
- journal article
- clinical trial
- Published by Wiley in Acta Paediatrica
- Vol. 85 (4) , 446-449
Abstract
The aim of the study was to investigate the effect of carnitine supplementation in valproic acid (VPA) treated patients presenting with increased plasma ammonia concentrations. Plasma ammonia concentrations were recorded in 69 children and young adults on VPA monotherapy (25.6 ± 9.2 mg VPA/kg per day; mean plasma VPA concentration 68.8 ± 27.6 μg/1). Their mean plasma ammonia concentration was 80.2 ± 32.1 μg/dl (median 73.1/i,g/dl), A total of 24 patients (35.3%) presenting with ammonia concentrations >80 μg/dl were considered hyperammonaemic. Of these, 15/24 (22.1 %) showed ammonia concentrations > 100 μg/dl, even up to 194 μg/dl. In 48/69 patients, plasma carnitine concentrations could be determined. The plasma total carnitine (TC) concentrations were rather low (26.9 ± 8.8 μmol/l) compared to normal values obtained in our laboratory (40.9 ± 7.2 μmol/l). The percentage of free carnitine was considered decreased (2 per day divided into two equal doses). Their plasma ammonia and carnitine concentrations were re‐evaluated after a mean of 9.1 ± 4.0 days (median 9.0 days) and in 9 patients again after a mean of 79.6 ± 30.1 days (median 75 days) of L‐carnitine supplementation. Plasma ammonia concentrations decreased in all 15 patients. The decrease was 25.4 ± 11.2% (median 28.3%) after a mean of 9.1 ± 4.0 days and amounted to 46.0 ± 17.2% (median 48%) after 79.6 ± 30.1 days. L‐Carnitine supplementation led to an increase in plasma free carnitine of 11.6 ± 13.0% (median 15.6%) and to a further increase of 11.1 ± 8.4% (median 11.5%) when re‐evaluated a second time. The plasma ammonia concentrations were significantly correlated with the percentage of free plasma carnitine (r=—0.67; p < 0.0001). The results show that carnitine supplementation is a means of normalizing elevated plasma ammonia concentrations. However, we cannot conclude from our results whether this lowers the risk of developing a VPA‐induced Reye's‐like syndrome.Keywords
This publication has 26 references indexed in Scilit:
- Hepatotoxic effects in a child receiving valproate and carnitineThe Journal of Pediatrics, 1993
- Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapyBrain and Development, 1992
- Is 2‐Propyl‐4‐Pentenoic Acid, a Hepatotoxic Metabolite of Valproate, Responsible for Valproate‐Induced Hyperammonemia?Epilepsia, 1992
- Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in childrenThe Journal of Pediatrics, 1991
- AMMONIA AND CARNITINE CONCENTRATIONS IN CHILDREN TREATED WITH SODIUM VALPROATE COMPARED WITH OTHER ANTICONVULSANT DRUGSDevelopmental Medicine & Child Neurology, 1991
- Valproate, Carnitine Metabolism, and Biochemical Indicators of Liver FunctionEpilepsia, 1990
- Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproateBiochemical Medicine and Metabolic Biology, 1990
- Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapyThe Journal of Pediatrics, 1986
- Carnitine deficiency and hyperammonemia associated with valproic acid therapyThe Journal of Pediatrics, 1982
- Decreased serum carnitine in valproate induced Reye syndromeEuropean Journal of Pediatrics, 1982